Terns Pharmaceuticals Inc.
Merck to Acquire Terns Pharmaceuticals for $53.00 per Share in Cash
Summary
Terns Pharmaceuticals, Inc. has entered into a definitive agreement to be acquired by Merck for $53.00 per share in cash, representing a total equity value of approximately $6.7 billion. The acquisition, which is expected to close in the second quarter of 2026, is subject to certain conditions, including the approval of Terns' shareholders and regulatory clearances. The transaction values Terns at a 31% premium to its 60-day and a 42% premium to its 90-day volume-weighted average stock price. The acquisition is intended to expand Merck's presence in hematology with Terns' lead candidate, TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for certain patients with chronic myeloid leukemia.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement